| Literature DB >> 36015608 |
Salem S Salem1, Amr H Hashem1, Al-Aliaa M Sallam2, Ahmed S Doghish3,4, Abdulaziz A Al-Askar5, Amr A Arishi6, Amr M Shehabeldine1.
Abstract
Traditional cancer treatments include surgery, radiation, and chemotherapy. According to medical sources, chemotherapy is still the primary method for curing or treating cancer today and has been a major contributor to the recent decline in cancer mortality. Nanocomposites based on polymers and metal nanoparticles have recently received the attention of researchers. In the current study, a nanocomposite was fabricated based on carboxymethyl cellulose and silver nanoparticles (CMC-AgNPs) and their antibacterial, antifungal, and anticancer activities were evaluated. The antibacterial results revealed that CMC-AgNPs have promising antibacterial activity against Gram-negative (Klebsiella oxytoca and Escherichia coli) and Gram-positive bacteria (Bacillus cereus and Staphylococcus aureus). Moreover, CMC-AgNPs exhibited antifungal activity against filamentous fungi such as Aspergillus fumigatus, A. niger, and A. terreus. Concerning the HepG2 hepatocellular cancer cell line, the lowest IC50 values (7.9 ± 0.41 µg/mL) were recorded for CMC-AgNPs, suggesting a strong cytotoxic effect on liver cancer cells. As a result, our findings suggest that the antitumor effect of these CMC-Ag nanoparticles is due to the induction of apoptosis and necrosis in hepatic cancer cells via increased caspase-8 and -9 activities and diminished levels of VEGFR-2. In conclusion, CMC-AgNPs exhibited antibacterial, antifungal, and anticancer activities, which can be used in the pharmaceutical and medical fields.Entities:
Keywords: anticancer; antimicrobial; carboxymethyl cellulose; silver nanoparticles
Year: 2022 PMID: 36015608 PMCID: PMC9412901 DOI: 10.3390/polym14163352
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.967
Figure 1FTIR spectrum and XRD pattern of CMC-AgNPs.
Figure 2TEM image (A), SEM image (B), and SEM/EDX mapping analysis (C–E) of CMC-AgNPs.
Antimicrobial activity as indicated by a growth-inhibition zone of different concentrations of CMC-AgNPs and AgNPs against different strains of bacteria.
| Bacterial Strains | Growth-Inhibition Zone in mm (Mean ± SD) as Caused by Different Concentrations of CMC-AgNPs and AgNPs | ||||
|---|---|---|---|---|---|
| CMC-AgNPs 100 µg/mL | CMC-AgNPs 50 µg/mL | AgNPs 100 µg/mL | AgNPs 50 µg/mL | Ciprofloxacine | |
| 18.0 ± 0.91 | 12.0 ± 0.34 | 13.0 ± 0.81 | 8.2 ± 0.51 | 13.0 ± 2.3 | |
| 17.0 ± 0.63 | 12.0 ± 0.27 | 14.0 ± 0.39 | 9.6 ± 0.51 | 15.0 ± 1.8 | |
| 12.0 ± 0.41 | 8.5 ± 0.3 | 9.5 ± 0.37 | 7.5 ± 0.27 | 14 ± 3.2 | |
| 11.0 ± 0.97 | 8.3 ± 0.6 | 8.5 ± 0.16 | 6.5 ± 0.37 | 16 ± 1.9 | |
Each value is the mean ± SD of triplicate analysis.
The MIC values were determined by colorimetric assay (resazurin), MBC (99.9% kill) and MIC/MBC ratio of CMC-AgNPs against Klebsiella oxytoca, Escherichia coli, Staphylococcus aureus, and Bacillus cereus.
| Standard Bacterial Strains | MIC (μg/mL) | MBC (μg/mL) | MBC/MIC Ratio |
|---|---|---|---|
| 12.5 | 25.0 | 2 | |
| 12.5 | 25.0 | 2 | |
| 25.0 | 100.0 | 4 | |
| 50.0 | 150.0 | 3 |
Figure 3Antifungal activity of CMC-AgNPs and their start materials using agar well diffusion method.
Inhibition zone and MIC of CMC-AgNPs compared to starting materials.
|
|
|
|
| |||||
|---|---|---|---|---|---|---|---|---|
| IZ/mm | MIC mg/mL | IZ/mm | MIC mg/mL | IZ/mm | MIC mg/mL | IZ/mm | MIC mg/mL | |
| CMC | ND | ND | ND | ND | 9 | 0.5 | ND | ND |
| AgNO3 | ND | ND | ND | ND | 8 | 0.5 | ND | ND |
| CMC-AgNPs | ND | ND | 19 | 0.0312 | 15 | 0.125 | 16 | 0.125 |
| NS | ND | ND | 11 | 0.5 | 12 | 0.25 | ND | ND |
Figure 4In-vitro cytotoxic activities of CMC-AgNPs against MCF-7 and HepG2 cell lines. The results are shown as the mean ± SD. * Significantly different from the Taxol group at p < 0.001.
Figure 5Effect of CMC-AgNPs on VEGFR-2 (pg/mL) in HepG2 cells compared to taxol (A); effect of CMC-AgNPs on caspase-8 and caspase-9 (ng/mL) in HepG2 cells compared to taxol (B). The results are shown as the mean ± SD. * Significantly different from the control (HepG2 cells) group at p < 0.0001.
Figure 6CMC-AgNPs induce apoptosis in the HepG2. (A) Control, (B) CMC-AgNPs, and (C) a graphical representation for % of apoptotic and necrotic cells. * Significantly different from the control group at p < 0.0001.
Figure 7Flow cytometry analysis of the cell-cycle distribution of HepG2 cells. (A) Control, (B) CMC-AgNPs, and (C) a graphical represent of cell-cycle distribution analysis among different treated cells. * Significantly different from the control group at p < 0.0001.